Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Abstract The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type o...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2019-11-01
|
| Serija: | Molecular Cancer |
| Teme: | |
| Online pristup: | http://link.springer.com/article/10.1186/s12943-019-1091-2 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|